Has the recent SBRT vs HDR monotherapy analysis changed your use of HDR monotherapy for intermediate-risk prostate cancer?

With excellent outcomes with SBRT in this group (PACE-B), the additional advantage of brachy is limited. The predominant use of HDR brachy is either as a boost for high-risk or as salvage after previous EBRT.

My short answer is that I continue to consider both SBRT and HDR as acceptable standards of care for localized, intermediate-risk prostate cancer. Although this study does present a provocative conclusion, I ultimately ran into some trouble understanding the methodology easily from the paper, which ...

Unfortunately, there will probably never be a head-to-head randomized comparison of SBRT vs HDR monotherapy, given the non-invasive nature of the former vs the latter, so we are left with post-hoc comparisons of prospective trials of the 2 modalities separately and retrospective data. The Udovicich ...